Zydus Pharmaceuticals
- All
- News
-
Gujarat Pharma Firm Recalls Over 55,000 Medicine Bottles From US Market
The affected lot is manufactured by Ahmedabad-based Zydus Lifesciences and marketed in the US by New Jersey-based Zydus Pharmaceuticals (USA) Inc.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Zydus Cadila Begins Supply Of Covid Vaccine ZyCoV-D To Government
Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.
-
Drug Regulator Examining Zydus Cadila's Covid Vaccine For Children: Dr VK Paul
Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.
-
Zydus Cadila Shot For 12-18 Soon, Centre Informs Supreme Court
A new coronavirus vaccine developed by Indian pharmaceutical company Zydus Cadila will be available soon for those between 12-18 years of age, the central government said in an affidavit to the Supreme Court on Saturday.
-
Zydus Cadila May Seek Emergency Use Approval For Vaccine Next Week: Report
Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.
-
Human Trials Of Second COVID-19 Vaccine Candidate Begin
Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from Drugs Controller General of India (DCGI) earlier this month.
-
Second COVID-19 Vaccine Cleared For Phase I, II Human Trials In India
The Drug Controller General of India has approved pharmaceutical firm Zydus Cadila to start Phase I and Phase II human clinical trials of its COVID-19 vaccine. This is the second vaccine after Hyderabad-based Bharat Biotech's COVAXIN to get the approval.
-
Zydus Cadila Gets USFDA Nod To Drug That Treats Severe Acne Vulgaris
Zydus Pharmaceuticals has received the final approval from the USFDA to market Minocycline Hydrochloride Extended Release Tablets
-
Cadila Settles Patent Litigation Related To Anti-Seizure Drug
Drug firm Cadila Healthcare today said it has settled all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules with US-based Upsher-Smith Laboratories, Inc.
-
Zydus Cadila Partners Takeda For Chikungunya Vaccine
Drug firm Zydus Cadila today announced partnership with Japan's Takeda Pharmaceutical Company Ltd to develop vaccine for chikungunya.
-
Zydus To Sell Ulcerative Colitis Treatment Generic Drug In US Market
Drug firm Cadila Healthcare's US arm Zydus Pharmaceuticals (USA) Inc will start selling a generic version of Asacol HD, used for treatment of ulcerative colitis, in the American market from August 1, 2016.
-
Zydus Healthcare Buys 2 New Drug Applications From Teva
Zydus Healthcare, a subsidiary of Cadila Healthcare, today said it has acquired two abbreviated new drug applications (ANDAs) from Teva Pharmaceutical in the US for an undisclosed sum.
-
Zydus Group Firm Gets US Regulator's Nod for Drug
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals, USA, has received approval from the US Food and Drug Administration (FDA) to market Dextroamphetamine IR tablets, used in treating nervous system disorders, in the American market.
-
Zydus Pharma Inc Recalls 9,504 Bottles of Risperidone Tablets
The ongoing Class III US nationwide including Puerto Rico voluntary recall is for Risperidone orally disintegrating tablets in the strength of 2 mg, United States Food and Drug Administration (USFDA) said in it's Enforcement Report for the week of March 2.
-
Gujarat Pharma Firm Recalls Over 55,000 Medicine Bottles From US Market
The affected lot is manufactured by Ahmedabad-based Zydus Lifesciences and marketed in the US by New Jersey-based Zydus Pharmaceuticals (USA) Inc.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Zydus Cadila Begins Supply Of Covid Vaccine ZyCoV-D To Government
Pharmaceutical company Zydus on Wednesday announced that it has started the supplies of its COVID-19 vaccine ZyCoV-D to the Government of India against their order from its newly commissioned state-of-the-art.
-
Drug Regulator Examining Zydus Cadila's Covid Vaccine For Children: Dr VK Paul
Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.
-
Zydus Cadila Shot For 12-18 Soon, Centre Informs Supreme Court
A new coronavirus vaccine developed by Indian pharmaceutical company Zydus Cadila will be available soon for those between 12-18 years of age, the central government said in an affidavit to the Supreme Court on Saturday.
-
Zydus Cadila May Seek Emergency Use Approval For Vaccine Next Week: Report
Indian pharmaceutical major Zydus Cadila is likely to apply to the central drugs regulator seeking emergency use authorisation for its COVID-19 vaccine ZyCoV-D next week, official sources said on Friday.
-
Human Trials Of Second COVID-19 Vaccine Candidate Begin
Indian pharmaceutical giant Zydus Cadila has initiated the phase 1, 2 clinical trial to evaluate the safety and immunogenicity of coronavirus vaccine candidate by intradermal (injection) route in 1,048 subjects after the pharma company got approval from Drugs Controller General of India (DCGI) earlier this month.
-
Second COVID-19 Vaccine Cleared For Phase I, II Human Trials In India
The Drug Controller General of India has approved pharmaceutical firm Zydus Cadila to start Phase I and Phase II human clinical trials of its COVID-19 vaccine. This is the second vaccine after Hyderabad-based Bharat Biotech's COVAXIN to get the approval.
-
Zydus Cadila Gets USFDA Nod To Drug That Treats Severe Acne Vulgaris
Zydus Pharmaceuticals has received the final approval from the USFDA to market Minocycline Hydrochloride Extended Release Tablets
-
Cadila Settles Patent Litigation Related To Anti-Seizure Drug
Drug firm Cadila Healthcare today said it has settled all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules with US-based Upsher-Smith Laboratories, Inc.
-
Zydus Cadila Partners Takeda For Chikungunya Vaccine
Drug firm Zydus Cadila today announced partnership with Japan's Takeda Pharmaceutical Company Ltd to develop vaccine for chikungunya.
-
Zydus To Sell Ulcerative Colitis Treatment Generic Drug In US Market
Drug firm Cadila Healthcare's US arm Zydus Pharmaceuticals (USA) Inc will start selling a generic version of Asacol HD, used for treatment of ulcerative colitis, in the American market from August 1, 2016.
-
Zydus Healthcare Buys 2 New Drug Applications From Teva
Zydus Healthcare, a subsidiary of Cadila Healthcare, today said it has acquired two abbreviated new drug applications (ANDAs) from Teva Pharmaceutical in the US for an undisclosed sum.
-
Zydus Group Firm Gets US Regulator's Nod for Drug
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals, USA, has received approval from the US Food and Drug Administration (FDA) to market Dextroamphetamine IR tablets, used in treating nervous system disorders, in the American market.
-
Zydus Pharma Inc Recalls 9,504 Bottles of Risperidone Tablets
The ongoing Class III US nationwide including Puerto Rico voluntary recall is for Risperidone orally disintegrating tablets in the strength of 2 mg, United States Food and Drug Administration (USFDA) said in it's Enforcement Report for the week of March 2.
